Find disease awareness content and relevant supporting materials

Efficacy and Safety Study of Talimogene Laherparepvec Compared to Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) in Melanoma

The objective of this study is to evaluate the efficacy and safety of treatment with talimogene laherparepvec compared to subcutaneously...

1 min read
Source: Clinicaltrials.gov

Drug news

29/05/15

Talimogene laherparepvec Phase III OPTiM study results in metastatic melanoma published in Journal of Clinical Oncology- Amgen

Amgen has announced the publication of primary results from the Phase III OPTiM study in the Journal of Clinical Oncology...

1 min read

Drug news

19/12/15

EU approves Imlygic (talimogene laherparepvec) for metastatic melanoma- Amgen

Amgen has announced that the European Commission has approved the use of Imlygic (talimogene laherparepvec) for the treatment of adults...

1 min read

Drug news

02/06/13

Amgen announced Phase III detailed results of talimogene laherparepvec in Melanoma

Amgen has announced detailed results from a pivotal Phase III trial evaluating talimogene laherparepvec in patients with unresected stage IIIB,...

1 min read

Drug news

21/03/13

Phase III success for talimogene laherparepvec (Amgen) in Melanoma

Amgen has announced top-line results from the Phase III trial in Melanoma, which evaluated the efficacy and safety of talimogene...

1 min read

Drug news

07/05/15

FDA joint advisory panel recommends T-Vec (talimogene laherparepvec) for treatment of metastatic melanoma- Amgen

A joint FDA Advisory Panel (Cellular,Tissue and Gene Therapy and Oncologic Drugs ) has voted to recommend approval to T-Vec...

1 min read

Drug news

03/09/14

Talimogene laherparepvec is filed at EMA for Melanoma- Amgen

Amgen has announced the submission of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) via the centralized...

1 min read

Clinical trial

01/12/05

A Study of Talimogene Laherparepvec in Stage IIIc and Stage IV Malignant Melanoma

The primary objective of the study was to assess the clinical efficacy of talimogene laherparepvec in terms of tumor response...

1 min read
Source: Clinicaltrials.gov

Drug news

24/10/15

CHMP recommends Imlygic (talimogene laherparepvec) to treat unresectable melanoma- Amgen

Amgen has announced that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines...

1 min read

Drug news

13/02/15

FDA Advisory Committee to review T Vec (talimogene laherparepvec) for Metastatic Melanoma on 29 April 2015- Amgen

Amgen has announced that the Cellular, Tissue and Gene Therapies Advisory Committee (CTGTAC) and the Oncologic Drugs Advisory Committee (ODAC)...

1 min read